- Home
- OCEAW vs CCIA Comparison
OCEAW vs CCIA Comparison
Compare OCEAW & CCIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCEAW
- CCIA
- Stock Information
- Founded
- OCEAW N/A
- CCIA N/A
- Country
- OCEAW United States
- CCIA
- Employees
- OCEAW 7
- CCIA N/A
- Industry
- OCEAW Biotechnology: Pharmaceutical Preparations
- CCIA
- Sector
- OCEAW Health Care
- CCIA
- Exchange
- OCEAW Nasdaq
- CCIA Nasdaq
- Market Cap
- OCEAW N/A
- CCIA N/A
- IPO Year
- OCEAW 2021
- CCIA 2023
- Fundamental
- Price
- OCEAW $0.02
- CCIA $25.70
- Analyst Decision
- OCEAW
- CCIA
- Analyst Count
- OCEAW 0
- CCIA 0
- Target Price
- OCEAW N/A
- CCIA N/A
- AVG Volume (30 Days)
- OCEAW N/A
- CCIA N/A
- Earning Date
- OCEAW N/A
- CCIA N/A
- Dividend Yield
- OCEAW N/A
- CCIA N/A
- EPS Growth
- OCEAW N/A
- CCIA N/A
- EPS
- OCEAW N/A
- CCIA N/A
- Revenue
- OCEAW N/A
- CCIA N/A
- Revenue This Year
- OCEAW N/A
- CCIA N/A
- Revenue Next Year
- OCEAW N/A
- CCIA N/A
- P/E Ratio
- OCEAW N/A
- CCIA N/A
- Revenue Growth
- OCEAW N/A
- CCIA N/A
- 52 Week Low
- OCEAW N/A
- CCIA N/A
- 52 Week High
- OCEAW N/A
- CCIA N/A
- Technical
- Relative Strength Index (RSI)
- OCEAW N/A
- CCIA 46.04
- Support Level
- OCEAW N/A
- CCIA $25.61
- Resistance Level
- OCEAW N/A
- CCIA $25.89
- Average True Range (ATR)
- OCEAW 0.00
- CCIA 0.24
- MACD
- OCEAW 0.00
- CCIA -0.02
- Stochastic Oscillator
- OCEAW 0.00
- CCIA 27.27
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.
About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.